Index by author
May 01, 2006; Volume 34,Issue 5
A
Abadie, Catherine
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
Abe, Takaaki
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Aizawa, Yoshio
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Akiyama, Yuji
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Atack, John R.
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
B
Balakrishnan, Anand
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Baldeck, Jean-Pierre
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Becker, Stacey
- You have accessEVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATIONStacey Becker and Xingrong LiuDrug Metabolism and Disposition May 2006, 34 (5) 855-861; DOI: https://doi.org/10.1124/dmd.105.007914
Berthier, Stephane
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Bertino, Joseph S.
- You have accessDURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAMJoseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. BertinoDrug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
Blanchard, Andrew P.
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
C
Caldwell, G. W.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Chandler, Catherine
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Charman, William N.
- You have accessAN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RATNatalie L. Trevaskis, Christopher J.H. Porter and William N. CharmanDrug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102
Chen, Chieh-Fu
- You have accessOXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu ChenDrug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
Cheng, Peter T.
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
Chiang, John Y. L.
- You have accessRIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSIONTiangang Li and John Y. L. ChiangDrug Metabolism and Disposition May 2006, 34 (5) 756-764; DOI: https://doi.org/10.1124/dmd.105.007575
Clark, Robert J.
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Clarke, Ashley
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Cook, Susan M.
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Crespi, Charles L.
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
D
Dai, Yang
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
Davis, Connie L.
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
Dawson, Gerard R.
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Dehal, Shangara S.
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Don, Ming-Jaw
- You have accessOXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu ChenDrug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
Dorani, Hassan
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
E
Eriksson, Ulf G.
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Everett, Donald W.
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
F
Fritsch, Holger
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Fukuda, Hajime
- You have accessEFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATERikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi TamaiDrug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
Fuse, Eiichi
- You have accessINHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECIDHarunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi SugiyamaDrug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
G
Galemmo, R. A.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Gauthier, D.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Gilmore, W. James
- You have accessTHE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTESMichael A. Terner, W. James Gilmore, Yanping Lou and E. James SquiresDrug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128
Glaenzel, Ulrike
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Goda, Rika
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Grassberger, Maximilian A.
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Grimm, Scott
- You have accessATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEINLiyue Huang, Yi Wang and Scott GrimmDrug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534
H
Haining, Robert L.
- You have accessTHE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. ZeldinDrug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
Halkic, Nermin
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
Hart, Heather L.
- You have accessTHE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. ZeldinDrug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
Hartmann, Stefan
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Hebert, Mary F.
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
Heyd, Bruno
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
Ho, C. Y.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Ho, Li-Kang
- You have accessOXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu ChenDrug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
Ho, Thuy
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Hoffmann, Kurt-Jürgen
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Huang, Liyue
- You have accessATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEINLiyue Huang, Yi Wang and Scott GrimmDrug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534
Humphreys, Joan E.
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Humphreys, W. Griffith
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
I
Ikeda, Toshihiko
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Ikemoto, Isao
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Isoherranen, Nina
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
J
Jan, Woan-Ching
- You have accessOXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu ChenDrug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
Johnson, D. L.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Johnson, Jennifer
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Jones, W. J.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
K
Kamikozawa, Yukari
- You have accessEFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATERikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi TamaiDrug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
Kamimura, Hidetaka
- You have accessTHE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITORDaisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi SawadaDrug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
Karlsson, Johan
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Kawai, Kenji
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Keogh, John P.
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Koepsell, Hermann
- You have accessINHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECIDHarunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi SugiyamaDrug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
Kunta, Jeevan R.
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Kusuhara, Hiroyuki
- You have accessINHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECIDHarunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi SugiyamaDrug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
L
Leo, G. C.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Li, Tiangang
- You have accessRIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSIONTiangang Li and John Y. L. ChiangDrug Metabolism and Disposition May 2006, 34 (5) 756-764; DOI: https://doi.org/10.1124/dmd.105.007575
Li, Wenying
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
Liguori, Michael J.
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
Liu, Siyu
- You have accessDURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAMJoseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. BertinoDrug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
Liu, Xingrong
- You have accessEVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATIONStacey Becker and Xingrong LiuDrug Metabolism and Disposition May 2006, 34 (5) 855-861; DOI: https://doi.org/10.1124/dmd.105.007914
Lou, Yanping
- You have accessTHE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTESMichael A. Terner, W. James Gilmore, Yanping Lou and E. James SquiresDrug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128
Ludington, Shana S.
- You have accessTHE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. ZeldinDrug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
M
Ma, Joseph D.
- You have accessDURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAMJoseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. BertinoDrug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
Maeda, Kazuya
- You have accessINHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECIDHarunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi SugiyamaDrug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
Mantion, Georges
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
Marsh, Christopher
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
Masucci, J. A.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
McKernan, Ruth M.
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Mei, J.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Moenius, Thomas
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
N
Nafziger, Anne N.
- You have accessDURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAMJoseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. BertinoDrug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
Nagai, Daichi
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Nagata, Kiyoshi
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Nakagomi-Hagihara, Rie
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Nakai, Daisuke
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Nishikawa, Kiyohiro
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Noguchi, Kiyoshi
- You have accessTHE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITORDaisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi SawadaDrug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
O
Ohashi, Rikiya
- You have accessEFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATERikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi TamaiDrug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
Ohtani, Hisakazu
- You have accessTHE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITORDaisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi SawadaDrug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
Olsson, Lis
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
P
Paine, Mary F.
- You have accessTHE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. ZeldinDrug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
Pike, Andy
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Polli, Joseph W.
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Porter, Christopher J.H.
- You have accessAN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RATNatalie L. Trevaskis, Christopher J.H. Porter and William N. CharmanDrug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102
R
Rautio, Jarkko
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Rettie, Allan E.
- You have accessTHE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. ZeldinDrug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
Rhodes, Gerry
- You have accessDURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAMJoseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. BertinoDrug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
Richert, Lysiane
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
S
Sarich, Troy C.
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Sawada, Yasufumi
- You have accessTHE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITORDaisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi SawadaDrug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
Schützer, Kajs-Marie
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Schweitzer, Alain
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Serabjit-Singh, Cosette J.
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Shen, Danny D.
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
Sohal, Bindi
- You have accessRAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. DawsonDrug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973
Squires, E. James
- You have accessTHE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTESMichael A. Terner, W. James Gilmore, Yanping Lou and E. James SquiresDrug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128
Stresser, David M.
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Sugiura, Mika
- You have accessEFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATERikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi TamaiDrug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
Sugiyama, Yuichi
- You have accessINHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECIDHarunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi SugiyamaDrug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
T
Tahara, Harunobu
- You have accessINHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECIDHarunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi SugiyamaDrug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
Tamai, Ikumi
- You have accessEFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATERikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi TamaiDrug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
Tenmizu, Daisuke
- You have accessTHE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITORDaisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi SawadaDrug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
Terner, Michael A.
- You have accessTHE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTESMichael A. Terner, W. James Gilmore, Yanping Lou and E. James SquiresDrug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128
Thummel, Kenneth E.
- You have accessEFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITROYang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. ThummelDrug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
Tokui, Taro
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Trevaskis, Natalie L.
- You have accessAN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RATNatalie L. Trevaskis, Christopher J.H. Porter and William N. CharmanDrug Metabolism and Disposition May 2006, 34 (5) 729-733; DOI: https://doi.org/10.1124/dmd.105.008102
Tuman, R. W.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
U
Ueng, Yune-Fang
- You have accessOXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu ChenDrug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
W
Waldmeier, Felix
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Wall, Ulrika
- You have accessINFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETIONUlf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie SchützerDrug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Wang, Lifei
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
Wang, Shu-Yun
- You have accessOXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu ChenDrug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
Wang, Yi
- You have accessATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEINLiyue Huang, Yi Wang and Scott GrimmDrug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534
Waring, Jeffrey F.
- You have accessGENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATINGLysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. WaringDrug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
Webster, Lindsey O.
- You have accessIN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATESJarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. PolliDrug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
Wong, James
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Y
Yabuuchi, Hikaru
- You have accessEFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATERikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi TamaiDrug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
Yamazoe, Yasushi
- You have accessDETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTSRika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi YamazoeDrug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
Yan, Z.
- You have accessN-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASESZ. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. JohnsonDrug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
Yoshigae, Yasushi
- You have accessOATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKERRie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko IkedaDrug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
Z
Zeldin, Darryl C.
- You have accessTHE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. ZeldinDrug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
Zenke, Gerhard
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Zhang, Donglu
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
Zhang, Duxi
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
Zhang, Hao
- You have accessBIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITESWenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith HumphreysDrug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
Zhang, J. George
- You have accessHUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81J. George Zhang, Shangara S. Dehal, Thuy Ho, Jennifer Johnson, Catherine Chandler, Andrew P. Blanchard, Robert J. Clark, Charles L. Crespi, David M. Stresser and James WongDrug Metabolism and Disposition May 2006, 34 (5) 734-737; DOI: https://doi.org/10.1124/dmd.105.006569
Zimmerlin, Alfred G.
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
Zollinger, Markus
- You have accessPIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITROMarkus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. GrassbergerDrug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
In this issue

Advertisement